Metabolic Modulation of the Tumor Microenvironment Leads to Multiple Checkpoint Inhibition and Immune Cell Infiltration
- 22 September 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 14 (9), 11055-11066
- https://doi.org/10.1021/acsnano.9b10037
Abstract
Cancer cells are known to be glycolytic, driving increased glucose consumption and its conversion to lactate. This process modulates the tumor microenvironment (TME). In the TME, glycolytically activated immune cells often become anergic, leading to an increase in immune checkpoint proteins such as programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). Most glycolytic inhibitors not only inhibit glycolysis of cancer but also of immune cells. Therefore, using a nanoparticle-delivered agent to preferentially inhibit glycolysis in tumor cells, and not in immune cells, has the potential to attenuate the expression of checkpoint proteins. Pyruvate dehydrogenase kinase 1 (PDK1) can be an important target to achieve tumor specific glycolysis inhibition. We report TME modulation by a mitochondrion-targeted nanoparticle (NP) containing a prodrug of dichloroacetate (DCA), a PDK1 inhibitor. We demonstrated that the targeted NP alters the TME which results in increased immunological activation against cancer cells, causing a decrease in mean tumor volume. Here, we also show findings that when Mito-DCA, a prodrug of DCA, was combined with anti-PD-1, a checkpoint inhibitor, results from in vivo syngeneic models showed an upregulation in the number of tumor infiltrating lymphocytes. This work provides a platform to bring therapeutic efficacy by selectively inhibiting glycolysis of cancer cells.Keywords
Funding Information
- Florida Department of Health (8BC10)
- Partikula LLC
- Sylvester Comprehensive Cancer Center, University of Miami Health Systems
This publication has 50 references indexed in Scilit:
- Succinate dehydrogenase expression in breast cancerSpringerPlus, 2013
- Pyruvate dehydrogenase kinase as a novel therapeutic target in oncologyFrontiers in Oncology, 2013
- Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeuticsProceedings of the National Academy of Sciences of the United States of America, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETCInternational Journal of Cancer, 2010
- Anergic T Cells Are Metabolically AnergicThe Journal of Immunology, 2009
- Tumor suppressors and cell metabolism: a recipe for cancer growthGenes & Development, 2009
- SorafenibDrugs, 2009
- Immune-mediated dormancy: an equilibrium with cancerJournal of Leukocyte Biology, 2008
- Cancer immunoediting from immune surveillance to immune escapeImmunology, 2007